Stock MXCT MAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases MaxCyte, Inc.

Equities

MXCT

US57777K1060

Market Closed - London S.E.
Other stock markets
 16:35:12 03/05/2024 BST 		5-day change 1st Jan Change
297 GBX 0.00% Intraday chart for MaxCyte, Inc. +0.68% -15.74%
05-03 Jefferies cuts AJ Bell; Deutsche likes ConvaTec AN
04-02 MaxCyte inks deal with Be Bio; Orcadian firms farmout AN

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
GL
MaxCyte, Inc. - Exercise of options and PDMR dealing
AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B cell Medicines
AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
GL
MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing
AQ
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
GL
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
AQ
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
GL
MaxCyte, Inc. - Exercise of options and PDMR dealing
AQ
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
GL
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
AQ
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
AQ
MaxCyte announces filing of Form 8-K
AQ
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
GL
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
GL
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
AQ
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
GL
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
AQ
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
GL
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MXCT Stock
  4. News MaxCyte, Inc.
  5. Press Releases